Premium
Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
Author(s) -
Narita Tomohiko,
Oiso Naoki,
Taketomo Yasunori,
Okahashi Kazunori,
Yamauchi Kohei,
Sato Masako,
Uchida Shusuke,
Matsuda Hiromasa,
Kawada Akira
Publication year - 2016
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.13028
Subject(s) - nivolumab , medicine , subclinical infection , vitiligo , euthyroid , autoimmune disease , disease , thyroid , serology , autoimmunity , diabetes mellitus , immunology , autoimmune thyroiditis , thyroiditis , cancer , endocrinology , antibody , immunotherapy
Nivolumab, a blockade of programmed cell death 1, is now administrated for advanced malignant melanomas. Nivolumab‐associated adverse events include organ‐specific autoimmune disorders; autoimmune thyroid disease, vitiligo and insulin‐dependent diabetes. However, predisposed persons are currently unknown. Here, we report serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab: one with Hashimoto disease and another with probable subclinical Hashimoto disease. We should verify if nivolumab‐related hypothyroidism and hyperthyroidism are predisposed to occur in euthyroid individuals with subclinical autoimmune thyroid disease.